Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma

Summary

This study will test the ability of a specially designed monoclonal antibody to destroy multiple myeloma cells. This antibody is unique in its ability to promote the death of multiple myeloma cells by processes known as antibody dependent cellular cytotoxicity (ADCC)and complement dependent cytotoxicity (CDC). The study is designed to determine both the optimal dose of the antibody to destroy multiple myeloma cells and frequency of dosing.

Timeline

Start

2008-10

Primary completion

2011-05

Completion

2011-10

Outcome

Outcome not reported

Stopped: “lack of efficacy in Multiple myeloma”

Publications

• Baz RC, Zonder JA, Gasparetto C, Reu FJ, Strout V. Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma. Oncol Ther. 2016;4(2):287-301. doi: 10.1007/s40487-016-0034-y. Epub 2016 Nov 2.

Drugs

Indications